High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo

Journal of the International AIDS Society

Volumn 14, Issue 1, 2011, Pages

  Dagnra, Anoumou Y ^a   Vidal, Nicole ^b   Mensah, Akovi ^c   Patassi, Akouda ^d   Aho, Komi ^e   Salou, Mounerou ^a   Monleau, Marjorie ^b   Prince David, Mireille ^a   Singo, Assétina ^f   Pitche, Palokinam ^f   Delaporte, Eric ^b   Peeters, Martine ^b  

^a PNLS and Laboratoire BIOLIM   (Togo)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c Espoir Vie Togo (EVT)   (Togo)

^d University Hospital TOKOIN   (Togo)

^e Centre de Réflexion et d'Initiative Pour la Promotion de la Santé CRIPS   (Togo)

^f Programme National de Lutte Contre le Paludisme   (Togo)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DEMOGRAPHY; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PUBLIC HEALTH; TOGO; TREATMENT DURATION; VIROLOGY; VIRUS LOAD; VIRUS STRAIN; WORLD HEALTH ORGANIZATION; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MUTATION; PHYSIOLOGY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; PREVALENCE; TOGO; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79958131967     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-14-30     Document Type: Article

References (17)

1. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. CF Gilks S Crowley R Ekpini S Gove J Perriens Y Souteyrand D Sutherland M Vitoria T Guerma K De Cock, Lancet 2006 368 505 10 10.1016/S0140-6736(06)69158-7 16890837 (Pubitemid 44142772)
2. WHO, Antiretroviral therapy for HIV infection in adults and adolescents.Recommendations for a public health approach: 2010 revision http://www.who.int/hiv/pub/arv/adult2010/en/index.html
3. UNAIDS, Epidemiological Fact Sheet on HIV and AIDS 2009 http://www.unaids.org/en/CountryResponses/Countries/togo.asp
4. Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. F Rouet V Foulongne J Viljoen K Steegen P Becquart D Valéa S Danaviah M Segondy C Verhofstede P Van de Perre WHO/ANRS 1289 Kesho Bora Study Group, J Virol Methods 2010 163 253 257 10.1016/j.jviromet.2009.10.005 19837114
5. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. L Vergne S Diagbouga C Kouanfack A Aghokeng C Butel C Laurent N Noumssi M Tardy A Sawadogo J Drabo H Hien L Zekeng E Delaporte M Peeters, Antivir Ther 2006 11 575 579 16964825 (Pubitemid 44277422)
6. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients. AY Dagnra N Vidal FR Niama M Prince-David E Delaporte M Peeters, Infect Genet Evol 2009 9 646 652 10.1016/j.meegid.2009.04.002 19460333
7. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. LC Ivers D Kendrick K Doucette, Clin Infect Dis 2005 41 217 224 10.1086/431199 15983918 (Pubitemid 40962502)
8. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. P Braitstein MW Brinkhof F Dabis M Schechter A Boulle P Miotti R Wood C Laurent E Sprinz C Seyler DR Bangsberg E Balestre JA Sterne M May M Egger Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups, Lancet 2006 367 817 824 16530575
9. Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis. C Seyler E Messou D Gabillard A Inwoley A Alioum X Anglaret, AIDS Res Hum Retroviruses 2007 23 1338 1347 10.1089/aid.2006.0308 18184075
10. Antiviral Therapy in Lower Income Countries (ART-LINC) Study Group. Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. F Dabis E Balestre P Braitstein P Miotti WG Brinkhof M Schneider M Schechter C Laurent A Boulle C Kabugo G Capkun C Seyler J McIntyre E Sprinz D Bangsberg S Van der Borght M Egger, Int J Epidemiol 2005 34 979 986 16157617 (Pubitemid 41535538)
11. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. C Laurent NF Ngom Gueye CT Ndour PM Gueye M Diouf N Diakhaté NC Touré Kane I Lanièce A Ndir L Vergne I Ndoye S Mboup PS Sow E Delaporte ANRS 1215/1290 Study Group, J Acquir Immune Defic Syndr 2005 38 14 17 10.1097/00126334-200501010-00003 15608518 (Pubitemid 40094112)
12. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. C Laurent C Kouanfack S Koulla-Shiro M Njoume YM Nkene L Ciaffi C Brulet G Peytavin L Vergne A Calmy E Mpoudi-Ngolé E Delaporte, AIDS 2007 21 768 771 10.1097/QAD. 0b013e328045c4d7 17413701 (Pubitemid 46568637)
13. Antiretroviral drug resistance and routine therapy, Cameroon. C Laurent C Kouanfack L Vergne M Tardy L Zekeng N Noumsi C Butel A Bourgeois E Mpoudi-Ngolé S Koulla-Shiro M Peeters E Delaporte, Emerg Infect Dis 2006 12 1001 1004 16707062 (Pubitemid 43848428)
14. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. RE Barth MF van der Loeff R Schuurman AI Hoepelman AM Wensing, Lancet Infect Dis 2010 10 155 166 10.1016/S1473-3099(09)70328-7 20185094
15. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. C Kouanfack C Montavon C Laurent A Aghokeng A Kenfack A Bourgeois S Koulla-Shiro E Mpoudi-Ngole M Peeters E Delaporte, Clin Infect Dis 2009 48 1318 1322 10.1086/597779 19320592
16. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. MC Hosseinipour JJ van Oosterhout R Weigel S Phiri D Kamwendo N Parkin SA Fiscus JA Nelson JJ Eron J Kumwenda, AIDS 2009 23 1127 1134 10.1097/QAD.0b013e32832ac34e 19417582
17. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. DE Bennett S Bertagnolio D Sutherland CF Gilks, Antivir Ther 2008 13 Suppl 2 1 13 18578063 (Pubitemid 352019085)